Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02202005 | Multiple Dose BE Study With Nevirapine 400mg PR Tablets | PHASE1 | COMPLETED | 46 | — | — | Aug 1, 2014 | Aug 1, 2015 | Aug 25, 2015 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Nevirapine | EXPERIMENTAL | - |
| Viramune® | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Nevirapine | DRUG | Nevirapine 400mg PR tablet |
| Viramune® | DRUG | Viramune® 400 mg Retardtabletten |
Inclusion Criteria: 1. Signed and dated written informed consent prior to admission to the study 2. HIV1 infected males or females of 18 to 65 years, nonsmoker (use of cannabis may be accepted) 3. Body weight ≥ 50.0 kg and BMI ≥ 18.0 and ≤ 32.0 kg/m2 4. Absence of clinically significant history of ...